soul trial oral semaglutide cardiovascular outcomes results Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Abstract 4367751: Cardiovascular Outcomes of
Description
SUPPORTS GLP-1 PRODUCTION These compounds help stimulate natural GLP-1 release, leading to better appetite control and improved insulin sensitivity
Future research should focus on longitudinal dietary assessment, biomarker monitoring, and validation of standardized nutrition protocols for patients receiving GLP1-based obesity pharmacotherapy.
Formula / M
Discover how peptides enhance your weight loss journey in Peoria
Key Takeaway: Mazdutide demonstrated superiority in combined glycemic control and weight loss
Skipping or missing a tirzepatide dose can disrupt your weight loss progress and metabolic control
